To further enhance efficacy, the combination of ghrelin agonists with other growth factors, such as EGF (Barco et al., 2011, del Barco et al., 2011, del Barco-Herrera et al., 2013; Subiros et al., 2016), GH (Wu et al., 2009b; Zhou et al., 2017), insulin (Granado et al., 2011) and GLP-1 (Duarte et al., 2018), or DAG, to prevent AG-encouraged glucose intolerance and hypoinsulinemia (Gauna et al., 2004; Kiewiet et al., 2009), may be profitable. Here, GHRL is linked to Glucose intolerance.